Health Rounds: Appendectomy appears to reduce ulcerative colitis relapses
April 16 (Reuters) - (To receive the full newsletter in your inbox for free sign up here)
Patients with the chronic inflammatory bowel disease ulcerative colitis might reduce their risk of a relapse by having their appendix removed, a new study suggests.
Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.
Ulcerative colitis causes inflammation and ulcers in the large intestine and rectum, with diarrhea and abdominal pain. There is no cure. Symptoms repeatedly subside and relapse and can adversely affect quality of life.
The appendix is thought to play a role in all of this by producing inflammatory proteins that trigger the body to produce cascades of immune responses, according to a report of the study published in The Lancet Gastroenterology & Hepatology, opens new tab.
All 197 adult patients in the current study were in remission at the start but had required treatment for an episode of active disease during the previous year.
All of them received the usual standard care. Half also had an appendectomy.
A year later, the relapse rates were 36% in the appendectomy group and 56% in the usual-care group, the researchers said.
In addition, fewer patients in the appendectomy group later developed more severe disease requiring treatment with biological agents.
There were five postoperative complications in the surgery group, including two that were labeled serious.
After accounting for patients' individual risk factors, the odds of relapse during the study were 35% lower with appendectomy.
'This significant... reduction suggests that appendectomy might be a viable additional therapeutic option for maintaining remission in ulcerative colitis,' the researchers wrote.
'Furthermore, patients who underwent appendectomy were significantly more likely to maintain lower disease activity, reduce the initiation of biological agents, and improve health-related quality of life compared with patients who received standard medical therapy alone.'
An editorial, opens new tab published with the study notes that a separate trial, still underway, is testing the benefit of appendectomy in patients whose ulcerative colitis is not in remission.
GSK ANTIBIOTIC SHOWS PROMISE FOR GONORRHEA
GSK's (GSK.L), opens new tab new pill for uncomplicated urinary tract infections in women and girls is also showing promise for treating uncomplicated gonorrhea, the company reported on Monday in The Lancet, opens new tab.
Gepotidacin, sold as Blujepa, is a first-in-class triazaacenaphthylene antibiotic that acts by inhibiting bacteria's replication of DNA.
In a late-stage, multi-nation trial, researchers randomly assigned 628 patients with gonorrhea in the urinary tract or genitals to treatment with gepotidacin or ceftriaxone with azithromycin.
Success rates at eradicating Neisseria gonorrhoeae bacteria were statistically similar, at 92.6% with gepotidacin and 91.2% with ceftriaxone plus azithromycin.
The gepotidacin group had higher rates of drug-related gastrointestinal adverse side effects, but almost all were mild or moderate, according to the researchers.
An editorial, opens new tab published with the report notes that no new antimicrobials have been introduced for gonorrhoea treatment since the 1990s.
The authors of the editorial expect N. gonorrhoeae to eventually develop resistance to gepotidacin, too.
However, they said gepotidacin should also be tested in patients with gonorrhea of the mouth and throat, which is harder to treat than the urogenital infections seen in the current trial.
An editorial in The Lancet Infectious Diseases, opens new tab notes that in a separate late-stage study, the first-in-class spiropyrimidinetrione antibiotic zoliflodacin was just as effective against urogenital gonorrhea as ceftriaxone plus azithromycin.
Zoliflodacin is being developed as part of a public-private partnership between Innoviva's (INVA.O), opens new tab specialty therapeutics unit and the Global Antibiotic Research & Development Partnership.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
17 hours ago
- Reuters
Novo's Ozempic, Wegovy linked to rare cases of dangerous eye disorder, EMA says
June 6 (Reuters) - The European Medicines Agency's safety committee has concluded that the use of Novo Nordisk's ( opens new tab popular weight-loss drug Wegovy and its treatments for type 2 diabetes may cause rare occurrences of a potentially dangerous eye condition. Called non-arteritic anterior ischemic optic neuropathy (NAION), the condition may affect up to 1 in 10,000 people taking semaglutide, the active ingredient in Wegovy and Novo's diabetes drugs Ozempic and Rybelsus, the regulator said on Friday. The EMA, which started its review in December, said the use of the drugs is linked to about twofold increase in the risk of developing the condition compared to people not taking the medicine. NAION develops from insufficient blood flow to the optic nerve and causes sudden painless vision loss in one eye. It is the second most common cause of blindness due to optic nerve damage, after glaucoma. Studies have linked semaglutide to NAION in the past. But this is the first time a regulator has made the link. Semaglutide belongs to a class of drugs known as GLP-1 receptor agonists, which work by helping control blood sugar levels and triggering a feeling of fullness. A large study of nearly 350,000 diabetics published earlier this year had showed that the risk of developing NAION more than doubled after long-term use of semaglutide, compared to patients taking medicines from other classes. The EMA said it has reviewed all available data on NAION with semaglutide, including data from non-clinical studies, clinical trials and post-marketing surveillance. It has recommended the drugmaker to update prescribing information for medicines containing semaglutide to include NAION as a side effect with a frequency of "very rare". The U.S. Food and Drug Administration did not immediately respond to a Reuters request for comment.
Reuters
17 hours ago
- Reuters
Health Rounds: Roche's Tecentriq reduces recurrence, deaths for certain colon cancer patients
June 6 (Reuters) - (This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays. To receive the full newsletter in your inbox for free sign up here.) Adding Roche's (ROG.S), opens new tab immunotherapy drug Tecentriq to chemotherapy after surgery in certain patients whose colon cancer had spread to the lymph nodes led to a 50% reduction in cancer recurrence and death compared to chemotherapy alone, according to trial data presented at recent medical meeting. Patients in the study had tumors with a genetic defect known as deficient DNA mismatch repair, or dMMR. About 15% of colon cancer patients have dMMR tumors, which do not respond well to chemotherapy. "The findings from our study represent a major advance in the adjuvant treatment of dMMR stage 3 colon cancer and will now change the treatment for this type of cancer," study leader Dr. Frank Sinicrope of the Mayo Clinic in Rochester, Minnesota said in a statement. The data, opens new tab were presented at the ASCO meeting that concluded earlier this week. The trial enrolled 712 patients with dMMR stage 3 colon cancer that had been surgically removed and who had cancer cells in their lymph nodes. Half of the study participants received chemotherapy along with Tecentriq, which activates the immune system to attack and kill cancer cells, for six months, followed by the immunotherapy alone for another six months. The other half of the patients received chemotherapy for 12 months. The benefit of Tecentriq was seen even in the oldest patients and those at particularly high-risk. "It's extremely rewarding to be able to offer our patients a new treatment regimen that can reduce the risk of recurrence and improve their chances of survival," Sinicrope said. As patients recover after a minimally invasive heart procedure, they might be better off continuing to take a certain type of blood-thinning drug to help prevent a heart attack or stroke, instead of continuing with the traditional aspirin, a new study suggests. Early after percutaneous coronary intervention (PCI) - a procedure to prop open blocked arteries either after a heart attack, or to prevent one - patients often receive dual anti-clotting therapy with both a P2Y12 inhibitor such as clopidogrel, the generic version of Plavix, or AstraZeneca's (AZN.L), opens new tab Brilinta (ticagrelor), and aspirin. After several months, patients are usually switched from dual therapy to lifelong daily aspirin use. But pooled data looking at patients who took part in five earlier clinical trials found that continuing to prescribe the P2Y12 inhibitors and stopping the aspirin was associated with lower rates of death, heart attack and stroke compared with continuing the aspirin, with no increased risk of major bleeding, researchers reported in The BMJ, opens new tab. Overall, the trials involved 16,117 patients who received either a P2Y12 inhibitor or aspirin after completing dual therapy following PCI. After an average follow-up period of around 4 years, P2Y12 inhibitor therapy was associated with a 23% lower risk of a composite of heart-related death, heart attack, or stroke, compared with aspirin, with no significant difference in major bleeding. That translates into one prevented cardiovascular death, heart attack, or stroke for every 46 patients taking a P2Y12 inhibitor instead of aspirin after dual therapy. Overall, the findings suggest that P2Y12 inhibitor drugs should be preferred over aspirin 'due to reductions in major adverse cardiac and cerebrovascular events without increasing major bleeding in the medium term,' according to an editorial published with the study. But the editorial said that since patients are advised to continue the post-PCI therapy for life, large trials directly comparing the different strategies with longer follow up are needed. Some diabetes and weight-loss drugs from the class known as GLP-1 agonists were linked with a small but elevated risk for an age-related eye disease in patients with diabetes, according to a study published on Thursday in JAMA Ophthalmology, opens new tab. In 139,000 patients with diabetes, including 46,334 who had been using the GLP-1 drugs semaglutide or lixisenatide, researchers identified 181 new cases of neovascular age-related macular degeneration, also known as wet AMD. Wet AMD is a degenerative eye disease marked by the abnormal growth of blood vessels under the retina that leak fluid or blood and can lead to blindness. The risk of developing AMD during up to three years of follow-up was low, at 0.2% in GLP-1 users versus 0.1% in non-users. Still, the researchers point out, after accounting for patients' individual risk factors, the odds of AMD were doubled with at least six months of GLP-1 use and tripled in patients with the longest duration of use. Semaglutide is the active ingredient in the widely used Novo Nordisk ( opens new tab drugs Ozempic and Wegovy, while lixisenatide is the main ingredient in Sanofi's ( opens new tab discontinued Adlyxin. GLP-1 drugs have also been associated with higher risks for an eye condition known as nonarteritic anterior ischemic optic neuropathy, or NAION. Researchers did not have information about the dose, route of administration, or frequency of administration of the medications used in the study. Even with that information, the study could not have proved cause and effect. At least one earlier study with longer follow up reported that GLP-1 use was linked with a lower, rather than higher, risk for AMD. 'Our findings are not directly contradictory' with that earlier report, said study leader Dr. Reut Shor of the University of Toronto. 'Factors such as timing and duration of exposure, disease stage, and patient characteristics may all influence outcomes," Shor said. "Our results add another layer to the emerging understanding of this complex relationship and emphasize the need for further research to clarify these trends.' (To receive the full newsletter in your inbox for free sign up here)
Reuters
18 hours ago
- Reuters
Contraceptives for poorest countries stuck in warehouses after US aid cuts
LONDON, June 5 (Reuters) - Contraceptives that could help prevent millions of unwanted pregnancies in some of the world's poorest countries are stuck in warehouses because of U.S. aid cuts and could be destroyed, two aid industry sources and one former government official said. The stock, held in Belgium and Dubai, includes condoms, contraceptive implants, pills and intrauterine devices, together worth around $11 million, the sources told Reuters. It has been stalled since the Trump administration started cutting foreign aid as part of its 'America First' policy in February, as the U.S. government no longer wants to donate the contraceptives or pay the costs for delivery, they said. The U.S. Agency for International Development (USAID) has instead asked the contractor managing its health supply chain, Chemonics, to try to sell it, two of the sources said. An internal USAID memo, sent in April, said a quantity of contraceptives was being kept in warehouses and they should be "immediately transferred to another entity to prevent waste or additional costs". A senior U.S. State Department official told Reuters no decision had been made about the future of the contraceptives. They did not respond to questions about the reasons why the contraceptives were in storage or the impact of the U.S. aid cuts and delays. A spokesperson for Chemonics said they were unable to comment on USAID's plans, but added that the company is working with clients to deliver life-saving aid globally and would continue to support the U.S. government's global health supply chain priorities. The stock represents just under 20% of the supply of contraceptives bought annually by the U.S. for donation overseas, a former USAID official told Reuters. Selling or donating the contraceptives has been challenging, according to the former USAID official, although talks are ongoing. Another option on the table is destroying it, at a cost of several hundred thousand dollars. As time goes on, shelf-lives will also become an issue, one of the sources said. The sources told Reuters that one of the key delays is a lack of response from the U.S. government about what should be done with the stock. It had been destined largely for vulnerable women in sub-Saharan Africa, including young girls who face higher health risks from early pregnancy as well as those fleeing conflict or who otherwise could not afford or access the contraceptives, the sources added. The condoms also help stop the spread of HIV, the former USAID official said. "We cannot dwell on an issue for too long; when urgency and clarity don't align, we have to move on," said Karen Hong, chief of UNFPA's supply chain. She said the agency is now working on Plan B to help fill critical supply gaps.
